6533b82ffe1ef96bd1295921
RESEARCH PRODUCT
Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder
Michele Pavone-macalusoCarlo PavoneG. CorselliVincenzo SerrettaS. PiazzaB. Piazzasubject
medicine.medical_specialtybusiness.industryCarcinoma in situmedicine.medical_treatmentUrologyGeneral Medicinemedicine.diseaseTransitional cell carcinomaConcomitantMedicineIn patientbusinessIntravesical chemotherapyAdjuvantdescription
The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1993-08-01 | Urologia Journal |